Koers Pathfinder Cell Therapy, Inc. Other OTC
Aandelen
PFND
US70319A1060
Biotechnologie & Medisch Onderzoek
Omzet 2013 | 0,05 0,05 | Omzet 2014 | - | Marktkapitalisatie | 534K 499K |
---|---|---|---|---|---|
Nettowinst (verlies) 2013 | -1 mln. -934K | Nettowinst (verlies) 2014 | -1 mln. -934K | EV/omzet 2013 | 246.023.185 x |
Nettoschuld 2013 | 3,94 mln. 3,69 mln. | Nettoschuld 2014 | 4,96 mln. 4,63 mln. | EV/omzet 2014 | - |
K/w-verhouding 2013 |
-5,48
x | K/w-verhouding 2014 |
-0,38
x | Werknemers | - |
Dividendrendement 2013 * |
-
| Dividendrendement 2014 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Rick Franklin
CEO | Chief Executive Officer | 78 | 02-09-11 |
John Benson
DFI | Director of Finance/CFO | 62 | 02-09-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rick Franklin
CEO | Chief Executive Officer | 78 | 02-09-11 |
John Benson
DFI | Director of Finance/CFO | 62 | 02-09-11 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,80% | 53,67 mld. | |
+35,79% | 38,86 mld. | |
-8,05% | 38,76 mld. | |
-8,98% | 27,27 mld. | |
+10,69% | 25,91 mld. | |
-16,21% | 20,29 mld. | |
+31,00% | 12,78 mld. | |
+28,51% | 12,18 mld. | |
-1,67% | 11,96 mld. |